ID   MDA-MB-231/PacR
AC   CVCL_4Z64
DR   cancercelllines; CVCL_4Z64
DR   Wikidata; Q54904617
RX   CelloPub=CLPUB00286;
RX   PubMed=25275030;
CC   Group: Triple negative breast cancer (TNBC) cell line.
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C5214; Breast adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0062 ! MDA-MB-231
SX   Female
AG   51Y
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 05-10-23; Version: 18
//
RX   CelloPub=CLPUB00286;
RA   Sprouse A.A.;
RT   "Resveratrol augments paclitaxel treatment in MDA-MB-231 and
RT   paclitaxel-resistant MDA-MB-231 breast cancer cells.";
RL   Thesis PhD (2014), University of Indiana, United States.
//
RX   PubMed=25275030;
RA   Sprouse A.A., Herbert B.-S.;
RT   "Resveratrol augments paclitaxel treatment in MDA-MB-231 and
RT   paclitaxel-resistant MDA-MB-231 breast cancer cells.";
RL   Anticancer Res. 34:5363-5374(2014).
//